In the late 1990s, lepirudin became an important recombinant hirudin-derived direct thrombin inhibitor, especially for patients with heparin-induced thrombocytopenia. It showed that anticoagulation could target thrombin directly rather than working through heparin or vitamin K pathways. This helped prepare the conceptual ground for later oral direct thrombin inhibitors such as dabigatran.

Lepirudin's introduction in 1998 marked a new era of direct thrombin inhibitors, linking ancient medicinal practices to modern science. This continuity inspired poets to explore themes of healing and the intersection of nature and technology, reflecting on the human experience.